Medicare Cuts Expected Spending on New Alzheimer Drugs
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Medicare is not forecasting significant spending on Leqembi and Kisunla in 2026 or 2027, a CMS spokesperson said.
- CMS had projected two years ago that it would spend billions annually on Leqembi alone.
- Leqembi and Kisunla are newly approved Alzheimer’s drugs that require intravenous infusion and extensive imaging, limiting patient eligibility.
Why it matters: Medicare avoids billions in drug costs while patients miss access to the only approved Alzheimer’s therapies; drug makers lose revenue and the health system sidesteps expensive treatments with limited efficacy and safety concerns.
Ask SkimNews
